Cyril Konto, M.D. has served as Chief Medical Officer since joining Ichnos and as the company’s Chief Executive Officer since May 2021. Previously, Cyril was Vice President of Clinical Development at Allogene Therapeutics, a spinoff from Pfizer, where he pioneered development of allogeneic CAR T-cell therapies. At Pfizer, he was Executive Director of Early Immuno-oncology Clinical Development. He began his industry career at Bristol Myers Squibb, first in medical affairs, and then in late-stage clinical development as clinical lead for the YERVOY® (ipilimumab) melanoma program. An oncologist by training, Cyril received his medical degree from University René Descartes in Paris and began practicing medicine at Pierre and Marie Curie University, where he held both clinical and academic positions.
What do you dare to imagine?
“A world where, as a result of the collective efforts of Ichnos and others in the oncology community, every cancer patient can be offered a cure.”
Roberto Giovannini, Ph.D., is responsible for leading CMC development at Ichnos Sciences. Roberto has more than 20 years of combined pharmaceutical and academic experience in the biotech sector with a focus on process development, covering all aspects of process development and scale-up. Previously, Roberto held multiple positions at Glenmark Pharmaceuticals and Boehringer Ingelheim, leading chemistry, manufacturing, and control (CMC) development for early- to late-stage development programs. Earlier in his career as a scientist, Roberto was at Bayer HealthCare, where he was in charge of process development for new therapeutics. He has a Ph.D. in purification of proteins from Ecole Polytechnique Fédérale de Lausanne and a master’s degree in chemistry from the University of Geneva.
What do you dare to imagine?
“Developing first-in-class treatments built on science that will make a positive impact on patients’ lives.”
Grace Maguire leads communications and corporate affairs at Ichnos Sciences. With more than 25 years of pharmaceutical industry experience across several therapeutic categories, Grace’s responsibilities have included setting commercial strategy, product launch, brand communications, and lifecycle management. Prior to Ichnos Sciences, she worked at Glenmark Pharmaceuticals as Vice President of Commercial for Specialty and Innovative Products, and at Forest Laboratories, Wyeth Pharmaceuticals, and Warner-Lambert. She began her career as a sales representative for Zeneca Pharmaceuticals in the New York City area. She has a master’s degree in business administration from the Leonard Stern School of Business at New York University and a bachelor’s degree in biology from St. John’s University in New York.
What do you dare to imagine?
“Working together to pursue the greatest challenges, with the hopes of offering physicians and patients real progress in treating disease.”
Michael Price serves as our Chief Financial Officer and has more than 25 years of biotechnology and pharmaceutical industry experience. Prior to joining Ichnos, he held the position of Executive Vice President and CFO at Akcea Therapeutics, Inc., where he helped manage all aspects of the business and worked closely with the executive team and independent directors on the Ionis Pharmaceuticals takeover. Prior to Akcea, Michael served as CFO at Novelion Therapeutics, Noven Pharmaceuticals, and Bentley Pharmaceuticals. He is a CPA and began his career with Price Waterhouse, now PWC.
Michael received his bachelor’s degree in accounting from Auburn University and his Master of Business Administration degree from Florida State University.
What do you dare to imagine?
“Working collaboratively to address the unmet needs of oncology patients and their families around the world.”
Martin Wilson is an accomplished attorney with more than 15 years of experience in the pharmaceutical industry. Martin joined Ichnos in January 2020 after serving as General Counsel, Chief Compliance Officer, Corporate Secretary and Head of Human Resources of Teligent, Inc. since 2017. Prior to joining Teligent, Martin served as Vice President and Assistant General Counsel for Endo Pharmaceuticals following the acquisition of Par Pharmaceuticals by Endo. Martin was with Par for over 11 years prior to the acquisition by Endo and served in a number of roles, including as Par’s Chief Compliance Officer. Martin received his B.S. from Saint Joseph’s University and a Juris Doctorate from Villanova University School of Law.
What do you dare to imagine?
“A future where Ichnos Sciences challenges the biotech ‘status quo’ and creates breakthroughs in medicine.”
Glenn Saldanha is the Chairman and Managing Director of Glenmark Pharmaceuticals Ltd. He joined in 1998 as Director and took over as Managing Director and CEO in 2001. As Chairman and Managing Director of Glenmark, Glenn oversees all operations of the organization. During his tenure, he transformed Glenmark into a truly global organization with revenues of more than $1 billion and a commercial presence in more than 50 countries. Under his leadership, Glenmark has evolved from a generics business into a research-driven and innovation-led organization. He holds a bachelor’s degree in pharmacy from Mumbai University in India and has a master’s degree in business administration from the Leonard Stern School of Business at New York University. Prior to Glenmark, he worked with Eli Lilly, USA and PricewaterhouseCoopers, USA.
David Lubner has more than 20 years of finance and executive leadership experience and served as Executive Vice President and Chief Financial Officer (CFO) of Ra Pharma, acquired by UCB Pharma in April 2020. Before joining Ra Pharma, David served as Senior Vice President, CFO at Tetraphase Pharmaceuticals, Inc., a biotechnology company focused on the discovery and development of novel antibiotics for the treatment of serious and life-threatening multidrug-resistant (MDR) bacterial infections. He also held CFO roles at PharMetrics, Inc., a leading patient-based pharmacy and medical claims data informatics company, and at ProScript, where Velcade® (bortezomib), a therapy widely used for treatment of the blood cancer multiple myeloma, was discovered. In addition, David serves on the Board of Directors of Dyne Therapeutics (Nasdaq: DYN), Therapeutics Acquisition Corporation (Nasdaq: RACA), and several other private companies and previously served on the Board of Directors of Nightstar Therapeutics until its acquisition by Biogen in June 2019. He is a Certified Public Accountant (CPA) in the Commonwealth of Massachusetts and a member of the American Institute of CPAs. David received his bachelor’s degree in accounting and business management from Northeastern University and a master’s degree in taxation from Bentley University.
V S Mani is the Executive Director & Global Chief Financial Officer of Glenmark Pharmaceuticals Limited. He is responsible for the company’s worldwide finance operations and secretarial function, including global accounting and financial reporting as well as tax and treasury functions. He is a qualified Chartered Accountant from India and has nearly 30 years of rich industry experience across treasury, taxation (direct, indirect, and international), accounting, financial planning and analysis, secretarial, legal, audits (internal and statutory), risk management, and investor relations. Prior to joining Glenmark in 2017, he was the President-Finance at the Bhartiya Group. He has also held the position of the Chief Financial Officer at Cipla Ltd. and played a key role in the acquisition of various companies in emerging and mature markets for the organization.
Lawrence Olanoff is currently an adjunct assistant professor and special advisor to the President for Corporate Relations at the Medical University of South Carolina. Previously, he served as President and Chief Operating Officer for Forest Laboratories, Inc. from 2006 through 2010. From 2005 to 2006, Dr. Olanoff was Chief Executive Officer of Celsion Corporation. He also served as Executive Vice President of Research and Development and Chief Scientific Officer of Forest from 1995 to 2005. Prior to joining Forest, Dr. Olanoff served in senior clinical research roles at Sandoz Pharmaceutical Corporation and at The Upjohn Company. During his pharmaceutical development career, Dr. Olanoff made substantial contributions leading to thirty new drug approvals, either as new chemical entities or as supplemental indications, over a range of therapeutic areas. He serves as a member of the Board of Ironwood Pharmaceuticals as well as several nonprofit organizations. Dr. Olanoff also held past directorships on the Boards of Forest Laboratories, Axovant Sciences Ltd., and the Celsion Corporation. He received his Ph.D. in biomedical engineering and M.D. degree from Case Western Reserve University, was an internal medicine resident and clinical pharmacology fellow at the Medical University of South Carolina, and is the author of some forty scientific publications on topics including controlled drug delivery, pharmacokinetics, drug metabolism, and clinical toxicology.
Jayaram Philkana is the President and Global Chief Human Resources Officer at Glenmark Pharmaceuticals Ltd. He is responsible for managing the organization’s diverse global talent, including talent acquisition, performance and rewards, leadership development, employee relations, and all other aspects of human resources strategies. Prior to joining Glenmark, he was the Global Chief Human Resources Officer at UPL Ltd. In addition, Jayaram previously worked with Cargill for more than 18 years and has held a wide range of leadership roles in the United States and Asia Pacific. Earlier in his career, he worked at PricewaterhouseCoopers, SmithKline Beecham, and British American Tobacco. He completed his postgraduate studies in human resources and industrial relations from XLRI School of Business, Jamshedpur, India.
Dennis Purcell is the original founder of Aisling Capital LLC and currently serves as a senior advisor. Previously, he served as the Senior Managing Partner. Prior to Aisling Capital, Dennis served as Managing Director of the Life Sciences Investment Banking Group at Chase H&Q (formerly Hambrecht & Quist) for more than five years. While at H&Q, he was directly involved with more than 200 completed transactions and supervised more than $10 billion of financing and advisory assignments in the pharmaceutical, biotechnology, and medical products industries. During his tenure, BioWorld Today and other industry publications cited H&Q as the leading underwriter of life sciences securities. Prior to joining H&Q, Dennis was a Managing Director in the Healthcare Group at PaineWebber, Inc. Dennis is a frequent commentator on the industry and has been honored in the “Biotech Hall of Fame” by Genetic Engineering & Biotechnology News, named to the Biotechnology All-Stars list by Forbes ASAP, honored as one of the top 50 Irish-American businessmen, and cited as one of the top 100 contributors to the biotechnology industry. He received his master’s degree in business administration from Harvard Business School and his bachelor’s degree in accounting from the University of Delaware.
The links above are provided for your convenience, and Ichnos is not responsible for content, privacy, or security issues associated with your visit to external websites.
Concerning Your Privacy